CS2009 + nab-paclitaxel

CS2009 + nab-paclitaxel is a **combination therapy** of CS2009 and nab-paclitaxel. **nab-paclitaxel** is an albumin-bound nanoparticle formulation of paclitaxel, designed to improve drug delivery and reduce toxicity compared to solvent-based paclitaxel. It acts as a microtubule inhibitor that disrupts mitosis in actively dividing cancer cells. nab-paclitaxel enhances tumor penetration and can deliver higher doses of paclitaxel with reduced hypersensitivity reactions, as it does not require cremophor or ethanol as solvents[1][2][4][5]. nab-paclitaxel (branded as Abraxane) has been approved for the treatment of multiple solid tumors, including metastatic breast cancer, non-small cell lung cancer, and metastatic pancreatic cancer[4]. **CS2009** is not found in publicly available pharmacological registries or clinical resources as of September 2025. Its identity, mechanism, and class remain unclear from the supplied data and current knowledge, though it is likely an investigational or code-named agent.

Other names

albumin-bound paclitaxelpaclitaxel albumin-bound nanoparticlesCS2009 + nab-paclitaxel